#Citius_Pharmaceuticals
LightNews LightNews
newsen.bsky.social
Citius Pharmaceuticals Announces Upcoming Participation in Investor Conferences in New York City#United_States#New_York#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals Announces Upcoming Participation in Investor Conferences in New York City
Citius Pharmaceuticals, Inc. is set to engage with investors at two significant conferences in October 2026, highlighting innovations in critical care.
third-news.com
October 12, 2026 at 12:39 PM
newsen.bsky.social
Citius Pharmaceuticals to Present Critical Innovations at September 2026 Investor Events#United_States#New_York#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals to Present Critical Innovations at September 2026 Investor Events
Citius Pharmaceuticals is set to engage investors at key conferences in September 2026, detailing its innovative healthcare products and advancements.
third-news.com
September 3, 2026 at 12:46 PM
newsen.bsky.social
Citius Pharmaceuticals Reports Strong Financial Growth in Q2 2026 with LYMPHIR Launch#United_States#Citius_Pharmaceuticals#Cranford,_New_Jersey#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals Reports Strong Financial Growth in Q2 2026 with LYMPHIR Launch
Citius Pharmaceuticals showcases significant growth in Q2 2026 with $5.6 million in revenue and successful advancement of LYMPHIR treatments.
third-news.com
May 15, 2026 at 8:43 PM
newsen.bsky.social
Citius Pharmaceuticals Successfully Completes $5 Million Offering to Advance Innovative Biopharmaceuticals#USA#CTXR#Cranford#Citius_Pharmaceuticals#LYMPHIR
Citius Pharmaceuticals Successfully Completes $5 Million Offering to Advance Innovative Biopharmaceuticals
Citius Pharmaceuticals has successfully closed a $5 million registered direct offering under Nasdaq rules, aimed at supporting the launch of its critical care product LYMPHIR.
third-news.com
April 24, 2026 at 8:35 PM
newsen.bsky.social
Citius Pharmaceuticals Grabs $3.8 Million from New Jersey's Economic Development Initiative#United_States#New_Jersey#Cranford#Citius_Pharmaceuticals#NOL_Program
Citius Pharmaceuticals Grabs $3.8 Million from New Jersey's Economic Development Initiative
Citius Pharmaceuticals has successfully obtained $3.8 million in non-dilutive capital from New Jersey's Economic Development Program, reinforcing its financial strength.
third-news.com
February 24, 2026 at 1:29 PM
newsen.bsky.social
Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch: A New Conquest in Oncology#United_States#Cranford#oncology#Citius_Pharmaceuticals#LYMPHIR
Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch: A New Conquest in Oncology
Citius Pharmaceuticals marks a significant milestone by announcing its first revenue from the newly launched LYMPHIR. This development points to a successful foothold in oncology, aiming to bring hope to patients.
third-news.com
February 13, 2026 at 1:16 PM
newsen.bsky.social
Citius Pharmaceuticals Completes $6 Million Direct Offering to Fuel Growth#United_States#Cranford#Citius_Pharmaceuticals#LYMPHIR#Nasdaq_CTXR
Citius Pharmaceuticals Completes $6 Million Direct Offering to Fuel Growth
Citius Pharmaceuticals has successfully finalized a direct offering worth $6 million. The proceeds will propel the launch of its innovative product, LYMPHIR, and further its development initiatives.
third-news.com
October 21, 2025 at 8:31 PM
newsen.bsky.social
Citius Pharmaceuticals Initiates $6 Million Direct Share Offering Under Nasdaq Regulations#United_States#Cranford#Citius_Pharmaceuticals#Clinical_Trials#LYMPHIR
Citius Pharmaceuticals Initiates $6 Million Direct Share Offering Under Nasdaq Regulations
Citius Pharmaceuticals announces a registered direct offering worth $6 million under Nasdaq regulations, aimed at supporting product development.
third-news.com
October 21, 2025 at 12:35 PM
newsen.bsky.social
Citius Pharmaceuticals and Citius Oncology Engage in Investor Conferences This October 2025#United_States#New_York#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals and Citius Oncology Engage in Investor Conferences This October 2025
Citius Pharmaceuticals and Citius Oncology are set to participate in key investor conferences in October 2025, showcasing their latest innovations.
third-news.com
October 17, 2025 at 9:06 PM
newsen.bsky.social
Citius Pharmaceuticals Reports Financial Results and Key Business Update for Q3 2025#USA#Citius_Pharmaceuticals#Mino-Lok#LYMPHIR#Cranford,_N.J.
Citius Pharmaceuticals Reports Financial Results and Key Business Update for Q3 2025
Citius Pharmaceuticals, Inc. has announced its fiscal Q3 2025 financial results, highlighting significant advances in product commercialization and financial health.
third-news.com
August 12, 2025 at 8:36 PM
newsen.bsky.social
Citius Oncology Successfully Closes $9 Million Public Offering for LYMPHIR Commercialization#USA#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology#Cranford,_NJ
Citius Oncology Successfully Closes $9 Million Public Offering for LYMPHIR Commercialization
Citius Oncology has completed a public offering, raising $9 million to advance its commercial efforts for the FDA-approved drug LYMPHIR. The funds will support its further development.
third-news.com
July 17, 2025 at 8:36 PM
newsen.bsky.social
Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing#United_States#NASDAQ#CTXR#Citius_Pharmaceuticals#Cranford,_New_Jersey
Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing
Citius Pharmaceuticals has successfully met the Nasdaq minimum bid price requirement, maintaining its listing after a period of compliance. The company continues to focus on critical care product development.
third-news.com
July 8, 2025 at 1:04 PM
newsen.bsky.social
Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development#United_States#CTXR#Cranford#Citius_Pharmaceuticals#LYMPHIR
Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development
Citius Pharmaceuticals has successfully closed a registered direct offering, raising $15.8 million, to support the launch of its oncology treatment LYMPHIR™ and other pharmaceuticals.
third-news.com
June 12, 2025 at 12:37 PM
newsen.bsky.social
Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon#United_States#CTXR#Cranford#Citius_Pharmaceuticals#LYMPHIR
Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon
Citius Pharmaceuticals shares financial updates and strategic plans, emphasizing their push towards the launch of LYMPHIR and enhanced market position.
third-news.com
May 14, 2025 at 8:41 PM
newsen.bsky.social
Citius Pharmaceuticals Set to Showcase Innovations at Jefferies Global Healthcare Conference 2025#USA#New_York#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals Set to Showcase Innovations at Jefferies Global Healthcare Conference 2025
Citius Pharmaceuticals, along with Citius Oncology, will present pivotal advancements at the Jefferies Global Healthcare Conference this June.
third-news.com
May 5, 2025 at 12:43 PM
newsen.bsky.social
Citius Pharmaceuticals' Q1 2025: Progress in Innovations and Financial Overview#United_States#Cranford#financial_results#Citius_Pharmaceuticals#LYMPHIR
Citius Pharmaceuticals' Q1 2025: Progress in Innovations and Financial Overview
Citius Pharmaceuticals released its financial results for Q1 2025, showcasing advancements in clinical trials while revealing a net loss amidst strategic growth plans.
third-news.com
February 14, 2025 at 9:36 PM
newsen.bsky.social
Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations#FDA_Approval#CTXR#Citius_Pharmaceuticals
Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations
Citius Pharmaceuticals has announced a pivotal $3 million registered direct offering, expanding its financial capabilities for product development and growth.
third-news.com
January 8, 2025 at 1:28 PM
newsen.bsky.social
Citius Pharmaceuticals Announces Launch Plans for LYMPHIR Immunotherapy in 2025#United_States#Cranford#Citius_Pharmaceuticals#LYMPHIR#Citius_Oncology
Citius Pharmaceuticals Announces Launch Plans for LYMPHIR Immunotherapy in 2025
Citius Pharmaceuticals is set to launch LYMPHIR, an innovative immunotherapy for relapsed cutaneous T-cell lymphoma, in early 2025.
third-news.com
January 7, 2025 at 2:06 PM
newsen.bsky.social
Citius Pharmaceuticals Reports Strong Financial Performance and Strategic Developments for Fiscal Year 2024#United_States#Citius_Pharmaceuticals#Mino-Lok#Cranford,_New_Jersey#LYMPHIR
Citius Pharmaceuticals Reports Strong Financial Performance and Strategic Developments for Fiscal Year 2024
Citius Pharmaceuticals, Inc. has made significant strides in 2024, achieving FDA approval for its new immunotherapy product and enhancing its financial strategies for future growth.
third-news.com
December 27, 2024 at 10:08 PM
newsen.bsky.social
Citius Pharmaceuticals Engages in Constructive FDA Meeting for Mino-Lok Approval Process#USA#FDA_Approval#Citius_Pharmaceuticals#Mino-Lok#Cranford,_New_Jersey
Citius Pharmaceuticals Engages in Constructive FDA Meeting for Mino-Lok Approval Process
Citius Pharmaceuticals reported a productive FDA meeting discussing the Phase 3 Mino-Lok program, paving the way for future approval.
third-news.com
November 25, 2024 at 1:12 PM